Log in

NASDAQ:HPTX - Horizon Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume786,899 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:HPTX
CUSIP44915N10
WebN/A
Phone+1-650-7457802

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive HPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HPTX and its competitors with MarketBeat's FREE daily newsletter.


Horizon Therapeutics (NASDAQ:HPTX) Frequently Asked Questions

What is Horizon Therapeutics' stock symbol?

Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HPTX."

How were Horizon Therapeutics' earnings last quarter?

Horizon Therapeutics Inc (NASDAQ:HPTX) announced its quarterly earnings data on Thursday, February, 26th. The biopharmaceutical company reported $0.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.67. The biopharmaceutical company earned $30.80 million during the quarter, compared to the consensus estimate of $24.60 million. Horizon Therapeutics's quarterly revenue was up 65.6% compared to the same quarter last year. View Horizon Therapeutics' Earnings History.

Has Horizon Therapeutics been receiving favorable news coverage?

Media headlines about HPTX stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Horizon Therapeutics earned a news impact score of -3.7 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the immediate future. View News Stories for Horizon Therapeutics.

Who are some of Horizon Therapeutics' key competitors?

What other stocks do shareholders of Horizon Therapeutics own?

How can I contact Horizon Therapeutics?

Horizon Therapeutics' mailing address is 2000 Sierra Point Pkwy Ste 400, BRISBANE, CA 94005-1849, United States. The biopharmaceutical company can be reached via phone at +1-650-7457802.


MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HPTX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  279
MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel